BR112017020408A2 - ?biotinas e composições? - Google Patents

?biotinas e composições?

Info

Publication number
BR112017020408A2
BR112017020408A2 BR112017020408A BR112017020408A BR112017020408A2 BR 112017020408 A2 BR112017020408 A2 BR 112017020408A2 BR 112017020408 A BR112017020408 A BR 112017020408A BR 112017020408 A BR112017020408 A BR 112017020408A BR 112017020408 A2 BR112017020408 A2 BR 112017020408A2
Authority
BR
Brazil
Prior art keywords
biotins
compositions
nmo
biotin
treatment
Prior art date
Application number
BR112017020408A
Other languages
English (en)
Portuguese (pt)
Inventor
Sedel Frédéric
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017020408(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of BR112017020408A2 publication Critical patent/BR112017020408A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
BR112017020408A 2015-03-26 2016-03-25 ?biotinas e composições? BR112017020408A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
BR112017020408A2 true BR112017020408A2 (pt) 2018-06-05

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020408A BR112017020408A2 (pt) 2015-03-26 2016-03-25 ?biotinas e composições?

Country Status (24)

Country Link
US (2) US10357480B2 (https=)
EP (2) EP3072513A1 (https=)
JP (1) JP6752874B2 (https=)
KR (1) KR20170131543A (https=)
CN (2) CN107405335A (https=)
AU (1) AU2016238759B2 (https=)
BR (1) BR112017020408A2 (https=)
CA (1) CA2980660A1 (https=)
CY (1) CY1122374T1 (https=)
DK (1) DK3273957T3 (https=)
EA (1) EA034394B1 (https=)
ES (1) ES2748354T3 (https=)
HR (1) HRP20191491T1 (https=)
HU (1) HUE046116T2 (https=)
IL (1) IL254619B (https=)
LT (1) LT3273957T (https=)
MA (1) MA41809B1 (https=)
ME (1) ME03567B (https=)
PL (1) PL3273957T3 (https=)
PT (1) PT3273957T (https=)
RS (1) RS59149B1 (https=)
SI (1) SI3273957T1 (https=)
SM (1) SMT201900548T1 (https=)
WO (1) WO2016151132A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
CN113164278B (zh) * 2018-12-11 2024-11-01 马优斯珀茨澳大利亚私人有限公司 粘合垫
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用
US20240082296A1 (en) * 2020-10-09 2024-03-14 Tx Medic Ab Treatment of muscle atrophy using dextran sulfate
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
UA86749C2 (en) 2002-09-27 2009-05-25 Байоджен Айдек Ма Инк. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
WO2012145746A1 (en) * 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
KR101951220B1 (ko) * 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
NZ735528A (en) 2021-09-24
AU2016238759A1 (en) 2017-10-05
JP6752874B2 (ja) 2020-09-09
US20190314342A1 (en) 2019-10-17
EP3072513A1 (en) 2016-09-28
CA2980660A1 (en) 2016-09-29
LT3273957T (lt) 2019-11-11
SMT201900548T1 (it) 2019-11-13
EP3273957A1 (en) 2018-01-31
EP3273957B1 (en) 2019-08-14
DK3273957T3 (da) 2019-11-11
US10357480B2 (en) 2019-07-23
IL254619B (en) 2020-03-31
WO2016151132A1 (en) 2016-09-29
CN107405335A (zh) 2017-11-28
SI3273957T1 (sl) 2019-11-29
PL3273957T3 (pl) 2020-01-31
EA034394B1 (ru) 2020-02-04
CY1122374T1 (el) 2021-01-27
ES2748354T3 (es) 2020-03-16
CN111973592A (zh) 2020-11-24
HRP20191491T1 (hr) 2019-11-15
IL254619A0 (en) 2017-11-30
KR20170131543A (ko) 2017-11-29
HUE046116T2 (hu) 2020-02-28
JP2018512451A (ja) 2018-05-17
US20180125825A1 (en) 2018-05-10
MA41809A (fr) 2018-01-30
EA201792124A1 (ru) 2018-04-30
RS59149B1 (sr) 2019-09-30
MA41809B1 (fr) 2019-12-31
AU2016238759B2 (en) 2020-08-06
PT3273957T (pt) 2019-09-18
ME03567B (me) 2020-07-20

Similar Documents

Publication Publication Date Title
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX381417B (es) Inhibidores de glucosidasa.
BR112018010118A2 (pt) inibidores de cxcr2
BR112016023558A2 (pt) compostos úteis como imunomoduladores
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
MX2015012644A (es) Tratamiento de cataplejia.
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
MX2016011072A (es) Derivado de pirazol amida.
BR112017020408A2 (pt) ?biotinas e composições?
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
MX2017007377A (es) Compuestos organicos.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112017008481A2 (pt) composto antimicótico
MX379262B (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX373603B (es) Activador de canales de kcnq2-5.
MY186907A (en) Hair growth agent
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]